Vor Biopharma VOR
$19.19 +$0.67 (+3.62%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $19.20 +0.05%
Open$18.14
Prev close$18.52
Day range$17.99 – $19.93
Volume1.56M
Market cap$1.18B
P/E (TTM)0.1
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$58.44M-107.9% YoY
Net profit-$86.73M+89.3% YoY
Diluted EPS-$1.45+98.8% YoY
Free cash flow-$32.77M+39.2% YoY
Operating cash flow-$32.75M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on assets402.6%
Current ratio13.50
Liabilities / assets127.6%
Cash & investments$481.55M
Total debt$2.44M
Net cash (debt)$479.11M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $58.44M | $47.85M | $35.16M | $371.64M | $35.96M |
| Selling and Admin Expenses | $23.91M | $21.93M | $17.57M | $50.11M | $16.77M |
| -General & Admin Expense | $23.91M | $21.93M | $17.57M | $50.11M | $16.77M |
| Research & Development | $34.53M | $25.92M | $17.60M | $321.53M | $19.19M |
| Operating Profit | -$58.44M | -$47.85M | -$35.16M | -$371.64M | -$35.96M |
| Net Non-Operating Interest Income (Expense) | $4.61M | $4.34M | $3.94M | $5.87M | $2.80M |
| Non-Operating Interest Income | $4.61M | $4.34M | $3.94M | $5.87M | $2.80M |
| Other Income (Expense) | -$32.89M | -$19.30M | -$188.36M | -$330.21M | $1.76B |
| Gain on Sale of Security | -$32.89M | -$19.30M | -$188.36M | -$334.36M | $1.76B |
| Pretax Profit | -$86.73M | -$62.81M | -$219.59M | -$695.98M | $1.72B |
| Net Profit | -$86.73M | -$62.81M | -$219.59M | -$695.98M | $1.72B |
| Profit from Continuing Operations | -$86.73M | -$62.81M | -$219.59M | -$695.98M | $1.72B |
| Net Income to Parent Company | -$86.73M | -$62.81M | -$219.59M | -$695.98M | $1.72B |
| Net Income to Common Stockholders | -$86.73M | -$62.81M | -$219.59M | -$695.98M | $1.72B |
| Basic EPS | -$1.45 | -$1.16 | -$5.11 | -$70.50 | $44.50 |
| Diluted EPS | -$1.45 | -$1.16 | -$5.11 | -$70.50 | $44.50 |
| Other Non-Operating Income (Expenses) | – | – | – | $4.15M | $2,000.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $496.31M | $481.05M | $506.75M | $464.13M | $464.13M |
| Total Current Assets | $490.52M | $475.11M | $500.78M | $458.11M | $458.11M |
| Cash and Cash Equivalents & Short-Term Investments | $481.55M | $466.13M | $491.53M | $455.21M | $455.21M |
| -Cash and Cash Equivalents | $78.98M | $107.86M | $169.87M | $396.49M | $396.49M |
| -Short Term Investments | $402.57M | $358.27M | $321.65M | $58.72M | $58.72M |
| Prepaid Assets | $4.97M | $5.88M | $6.39M | $1.15M | $1.15M |
| Other Current Assets | $4.01M | $3.10M | $2.86M | $1.75M | $1.75M |
| Total Non-Current Assets | $5.79M | $5.95M | $5.97M | $6.02M | $6.02M |
| Net PPE | $3.23M | $3.37M | $3.39M | $3.47M | $3.47M |
| -Gross PPE | $3.36M | $3.46M | $3.45M | $3.49M | $3.49M |
| -Accumulated Depreciation | -$128,000.00 | -$90,000.00 | -$53,000.00 | -$25,000.00 | -$25,000.00 |
| Other Non-Current Assets | $2.56M | $2.58M | $2.58M | $2.55M | $2.55M |
| Total Liabilities | $633.49M | $681.25M | $657.17M | $628.44M | $628.44M |
| Total Current Liabilities | $36.34M | $24.81M | $16.08M | $25.17M | $25.17M |
| Payables | $5.61M | $4.00M | $1.04M | $5.13M | $5.13M |
| -Accounts Payable | $5.61M | $4.00M | $1.04M | $5.13M | $5.13M |
| Current Accrued Expenses | $23.58M | $15.76M | $11.80M | $16.14M | $16.14M |
| Short-Term Debt and Capital Lease Obligation | $370,000.00 | $335,000.00 | $307,000.00 | $280,000.00 | $280,000.00 |
| -Current Capital Lease Obligation | $370,000.00 | $335,000.00 | $307,000.00 | $280,000.00 | $280,000.00 |
| Other Current Liabilities | $476,000.00 | – | $698,000.00 | $554,000.00 | $554,000.00 |
| Total Non-Current Liabilities | $597.14M | $656.44M | $641.09M | $603.27M | $603.27M |
| Long Term Debt and Capital Lease Obligation | $2.44M | $2.54M | $2.63M | $2.72M | $2.72M |
| -Long Term Capital Lease Obligation | $2.44M | $2.54M | $2.63M | $2.72M | $2.72M |
| Derivative Product Liabilities | $594.70M | $653.89M | $638.46M | $600.55M | $600.55M |
| Total Equity | -$137.17M | -$200.20M | -$150.42M | -$164.31M | -$164.31M |
| Stockholders' Equity | -$137.17M | -$200.20M | -$150.42M | -$164.31M | -$164.31M |
| Capital Stock | $20,000.00 | $19,000.00 | $19,000.00 | $18,000.00 | $18,000.00 |
| -Common Stock | $20,000.00 | $19,000.00 | $19,000.00 | $18,000.00 | $18,000.00 |
| -Preferred Stock | $0.00 | $0.00 | – | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.39B | $1.24B | $1.22B | $988.60M | $988.60M |
| Retained Earnings | -$1.52B | -$1.44B | -$1.37B | -$1.15B | -$1.15B |
| Gains/Losses Not Affecting Retained Earnings | -$1.85M | -$922,000.00 | -$706,000.00 | $41,000.00 | $41,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$32.75M | -$25.38M | -$38.25M | -$142.71M | -$22.80M |
| Net cash flow from continuing operations | -$32.75M | -$25.38M | -$38.25M | -$142.71M | -$22.80M |
| Net Income from Continuing Operations | -$86.73M | -$62.81M | -$219.59M | -$695.98M | $1.72B |
| Gain/Loss from Continuing Operations | $32.89M | – | – | $3.30M | -$2.09B |
| Depreciation & Depletion & Amortization | $39,000.00 | $36,000.00 | $28,000.00 | $2.89M | $23,000.00 |
| Other Non-Cash Items | -$1.27M | -$188.25M | $188.47M | $518.03M | $334.50M |
| Change in Working Capital | $11.46M | $9.01M | -$15.54M | $10.21M | $3.16M |
| -Change in Prepaid Assets | $4,000.00 | $278,000.00 | -$6.36M | $1.68M | -$873,000.00 |
| -Change in Payables and Accrued Expense | $11.51M | $8.80M | -$9.10M | $10.93M | $6.21M |
| -Change in Other Current Assets | $23,000.00 | -$7,000.00 | -$20,000.00 | $0.00 | -$2.11M |
| -Change in Other Current Liabilities | -$70,000.00 | -$62,000.00 | -$61,000.00 | -$2.41M | -$59,000.00 |
| Net cash flow from investing | -$44.78M | -$36.53M | -$263.24M | -$48.80M | -$48.97M |
| Net Cash Flow from Continuing Investing Activities | -$44.78M | -$36.53M | -$263.24M | -$48.80M | -$48.97M |
| Net PPE Purchase and Sale | -$25,000.00 | -$120,000.00 | -$48,000.00 | -$142,000.00 | -$314,000.00 |
| Net Investment Purchase and Sale | -$44.76M | -$36.41M | -$263.19M | -$48.66M | -$48.66M |
| Financing Cash Flow | $48.65M | -$106,000.00 | $74.87M | $503.81M | $307.80M |
| Net Cash Flow from Continuing Financing Activities | $48.65M | -$106,000.00 | $74.87M | $503.81M | $307.80M |
| Net Common Stock Issuance | $48.40M | $0.00 | $75.00M | $328.21M | $307.95M |
| Proceeds from Stock Option Exercised | $254,000.00 | $1,000.00 | -$2,000.00 | $176.93M | -$19,000.00 |
| Net Other Financing Charges | $0.00 | -$107,000.00 | -$127,000.00 | -$1.33M | -$131,000.00 |
| Ending Cash Balance | $79.15M | $108.02M | $170.04M | $396.65M | $396.65M |
| Net Change in Cash | -$28.88M | -$62.02M | -$226.61M | $312.29M | $236.02M |
| Beginning Cash Balance | $108.02M | $170.04M | $396.65M | $84.36M | $160.63M |
| Free Cash Flow | -$32.77M | -$25.50M | -$38.29M | -$143.65M | -$23.12M |
No comments yet — be the first to weigh in on VOR.
Sign in to join the discussion.